Biosimilar But Different: Zarxio, Neupogen Diverge On Syringes, Vials
Executive Summary
Differences in product presentation may not have much market impact now but could prove a regulatory challenge if Sandoz pursues an interchangeability determination down the line.
You may also be interested in...
Zarxio Syringe’s Limitations May Delay Decision On Neupogen Interchangeability
FDA review documents for Sandoz’s filgrastim-sndz suggest that biosimilar sponsors need to consider how differences in delivery device from the reference product will play out under the 351(k) pathway, including whether new device designs and human factors data will be needed to secure interchangeability.
How To Label A Biosimilar? Copy The Reference Product, FDA Told Sandoz
But agency had to weigh how presentation differences between Sandoz’s Zarxio and Amgen’s Neupogen, as well as Neupogen-specific safety information, should be reflected in the biosimilar’s labeling.
Biosimilars’ Generic-style Labeling Limits Data Promotion, Companies Say
Given dearth of biosimilar-specific data on label for Sandoz’s filgrastim-sndz, biosimilar sponsors say they need way to discuss their products’ analytical and clinical data with health care providers and payers, while physicians want more data about the biosimilar itself in labeling.